Search results
Your search for TFRC returned no results
Showing 2301 to 2350 of 2490 results for term
Showing 2301 to 2350 of 2490 results for term
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)
NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.
NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Agenda and papers of the NICE public board meeting on 22 March 2023
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)
NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
Find out more about NICE technology appraisals advisory committee D members
Bisphosphonates for treating osteoporosis Digestive tract conditions Long term heartburn treatment Gynaecological conditions and...
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Day-to-day decision making is the responsibility of NICE's executive team.
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.